Antipsychotic medications are the mainstay of treatment for schizophrenia. The recent advent the atypical antipsychotic has provided new clinical options and sets higher expectations for the treatment of schizophrenia. It is not yet clear how each different drug will fit within the therapeutic armamentarium and this lack is most evident with considering patients with treatment refractory schizophrenia. On the other hand, the expectation of superior efficacy, more benign side effect profile and potential to impact the longitudinal course of schizophrenia provide a rationale for the use novel antipsychotics as a first-line treatment of schizophrenia.
|Original language||English (US)|
|Number of pages||29|
|Journal||Psychiatric Clinics of North America|
|State||Published - 1998|
All Science Journal Classification (ASJC) codes
- Psychiatry and Mental health